



October 28, 2013

Safran SA – Ratio Change and Stock Distribution

DR CUSIP: 786584102
DR ISIN: US7865841024
DR Ticker Symbol: SAFRY

Please be advised that The Bank of New York Mellon, as Depositary, will change the ratio of the Safran SA, Depositary Receipt (“DR”) program from 1 DS representing 1 Ordinary share to the new ratio of 4 DSs representing 1 Ordinary share.

The ratio change will occur simultaneously with a 300% DS distribution (or 3 additional DSs for each 1 DS held).

Please note the following:

DR Record Date: November 6, 2013
DR Payable Date: November 7, 2013
DR Distribution Rate: 300% Distribution (or 3 additional DSs for each 1 DS held).
Old DR Ratio: 1 DS : 1 Ordinary share
New DR Ratio: 4 DSs : 1 Ordinary share
Effective date for DR ratio change: November 8, 2013

Please note: A ratio change may impact the fees payable by ADR investors.

Books will be closed from November 7, 2013 and will reopen on November 14, 2013 for Issuance and Cancellation transactions.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New York

Melissa Sobolewski/Ravi Davis
+1 212 815-2267
Adrdesk@bnymellon.com

London

Damon Rowan
Vice President
+44 207 964 6527
damon.rowan@bnymellon.com

Hong Kong

Herston Powers
Vice President
+852 2 840 9868
herston.powers@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; broker may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also transact with affiliate brokers and dealers. This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.